The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-23 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
== Medical uses == Relugolix is approved in the United States, Canada and the United Kingdom for the treatment of prostate cancer, in Japan for the treatment of uterine fibroids (uterine leiomyoma) and in the United Kingdom for endometriosis.
The group released one album in 1965 and three albums in 1966. Dino, Desi & Billy albums contained primarily versions of Top 40 songs made popular by others, with new content being minor. The three boys made an appearance in the Dean Martin film Murderers' Row and sang the Boyce & Hart song, "If You're Thinkin' What I'm Thinkin'". From 1966 to 1970, the group continued to release singles, encountering marginal success, which was not altered by a change of label to Columbia Records in 1969. Also in 1969, the group contributed three songs to the soundtrack of the surf film Follow Me. The group received top billing on the soundtrack album, despite the fact that most of the album featured music by composer Stu Phillips. Later in 1969 the group broke up, due in part to Desi joining his mother's television show and Hinsche wishing to commence university studies. The group was never a favorite of the critics. Writing for AllMusic, music critic Richie Unterberger characterized them as a group that "never had an ounce of credibility", with music that was "innocuously bland in the extreme." These sentiments may be contrasted with the fact that the band was well thought of by the Beach Boys, to the extent that Brian Wilson and Hinsche co-wrote one of the band's original songs, and their final single, "Lady Love". That single was released by Reprise Records in 1970, after the group had broken up. Hinsche's sister, Annie, married Carl Wilson and Hinsche himself worked with the Beach Boys as a backing musician for many years.
=== Drug delivery === Researchers at Monash University discovered that a sheet of graphene oxide can be transformed into liquid crystal droplets spontaneously—like a polymer—simply by placing the material in a solution and manipulating the pH. The graphene droplets change their structure in the presence of an external magnetic field. This finding raises the possibility of carrying a drug in graphene droplets and releasing the drug upon reaching the targeted tissue by making the droplets change shape in a magnetic field. Another possible application is in disease detection if graphene is found to change shape at the presence of certain disease markers such as toxins. A graphene 'flying carpet' was demonstrated to deliver two anti-cancer drugs sequentially to the lung tumor cells (A549 cell) in a mouse model. Doxorubicin (DOX) is embedded onto the graphene sheet, while the molecules of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are linked to the nanostructure via short peptide chains. Injected intravenously, the graphene strips with the drug payload preferentially concentrate to the cancer cells due to common blood vessel leakage around the tumor. Receptors on the cancer cell membrane bind TRAIL and cell surface enzymes clip the peptide thus release the drug onto the cell surface. Without the bulky TRAIL, the graphene strips with the embedded DOX are swallowed into the cells. The intracellular acidic environment promotes DOX's release from graphene. TRAIL on the cell surface triggers the apoptosis while DOX attacks the nucleus.
Sources: en.wikipedia.org
=== Manufactured products === Environmentally beneficial, low-cost substitutes for rigid thermoplastic and fired ceramic are made using sCO2 as a chemical reagent. The sCO2 in these processes is reacted with the alkaline components of fully hardened hydraulic cement or gypsum plaster to form various carbonates. The primary byproduct is water. sCO2 is used in the foaming of polymers. Supercritical carbon dioxide can saturate the polymer with solvent. Upon depressurization and heating, the carbon dioxide rapidly expands, causing voids within the polymer matrix, i.e., creating a foam. Research is ongoing on microcellular foams. An electrochemical carboxylation of a para-isobutylbenzyl chloride to ibuprofen is promoted under sCO2.
On 2 November 2010, Lions Gate Entertainment secured the North American distribution rights to Dredd. Headey joined the cast as drug-dealer Ma-Ma in January 2011. Judge Dredd creator John Wagner acted as a consultant on the film. In 2012, he confirmed that it was a new adaptation of the comic material and was not a remake of the 1995 adaptation Judge Dredd, which starred Sylvester Stallone.
Clinical chemistry (also known as chemical pathology, clinical biochemistry or medical biochemistry) is a division in pathology and medical laboratory sciences focusing on qualitative tests of important compounds, referred to as analytes or markers, in bodily fluids and tissues using analytical techniques and specialized instruments. This interdisciplinary field includes knowledge from medicine, biology, chemistry, biomedical engineering, informatics, and an applied form of biochemistry (not to be confused with medicinal chemistry, which involves basic research for drug development). The discipline originated in the late 19th century with the use of simple chemical reaction tests for various components of blood and urine. Many decades later, clinical chemists use automated analyzers in many clinical laboratories. These instruments perform experimental techniques ranging from pipetting specimens and specimen labelling to advanced measurement techniques such as spectrometry, chromatography, photometry, potentiometry, etc. These instruments provide different results that help identify uncommon analytes, changes in light and electronic voltage properties of naturally occurring analytes such as enzymes, ions, electrolytes, and their concentrations, all of which are important for diagnosing diseases. Blood and urine are the most common test specimens clinical chemists or medical laboratory scientists collect for clinical routine tests, with a main focus on serum and plasma in blood. There are now many blood tests and clinical urine tests with extensive diagnostic capabilities.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.